Clinical significance of serum triple monoclonal components: A report of 6 cases and a review of the literature

Guastafierro, Salvatore; Sica, Antonello; Parascandola, Rita Rosaria; Ferrara, Maurizio; Martino, Anna Di; Pezone, Lucia; Falcone, Umberto

doi:10.1016/j.leukres.2013.10.020

Cited by 9 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with a solitary lesion or limited lesions in a single anatomical site require different treatments if compared with patients with generalized lesions or refractory disease or extracutaneous (Figures 1A,B). Systemic symptoms are usually absent and the presence of a serum or urinary monoclonal component (MC) represents a very rare occurrence (11)(12)(13). Some authors have proposed the distinction of two subsets of PCMZL.…”

Section: Introductionmentioning

confidence: 99%

Primary Cutaneous B-Cell Lymphomas: An Update

et al. 2020

Self Cite

View full text Add to dashboard Cite

Primary cutaneous B-cell lymphomas (PCBCLs) comprise a group of extranodal B-cell non-Hodgkin lymphomas B-cell derived, which primarily involve the skin without evidence of extracutaneous disease at the time of diagnosis. They include ∼25% of all cutaneous lymphomas and are classified in three major subgroups (World Health Organization (WHO) 2017): primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center cell lymphoma (PCFCL), and diffuse large B-cell lymphoma, leg type (PCDLBCL, LT). This classification also includes some less common entities such as intravascular large B-cell lymphoma. Recently, WHO-EORTC added Epstein-Barr virus positive (EBV+) mucocutaneous ulcer, as a new provisional distinct entity, to cutaneous B-cell lymphomas. PCBCLs are classically characterized by patches, plaques, or nodules showing great variability for color, shape, and location. Diagnosis requires histological examination with immunohistochemical staining. In general, therapeutic options depend on the exact histological and immunohistochemical classification, disease presentation, and risk assessment. PCMZL and PCFCL are considered indolent lymphomas with a good prognosis and are associated with 5-year disease-specific survival ≥ 95%. In contrast, PCDLBCL, LT is considered an aggressive lymphoma with a survival rate in 5 years of lower than 60%. Patients with a solitary lesion or limited lesions in a single anatomical site require different treatments as compared to patients with generalized lesions or refractory disease or extracutaneous involvement. Therapeutic choice includes observation, local, or systemic therapy based on histology and disease extension. Patient management is multidisciplinary, including dermatologists, pathologists, hemato-oncologists, and radiation oncologists.

show abstract

Section: Introductionmentioning

confidence: 99%

Primary Cutaneous B-Cell Lymphomas: An Update

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since CR was achieved after 6 months of this third line of treatment, the donor selection for allo-SCT began. A haploidentical male cousin was summoned in December 2019 to undergo the first level investigations to be admitted to donation: HCV-Ab, HBsAg, HBcAb, HIV-Ab, blood count, creatinine, BUN, AST, ALT, amylase, lipase, bilirubin, electrolytes, triglyceride, cholesterol and glycemy, serum protein electrophoresis, LDH [19][20][21][22][23][24].…”

Section: Case Reportmentioning

confidence: 99%

How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas Alk+ Therapy: A Case Report

Sica¹,

Sagnelli²,

Casale³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: The t (2; 5) chromosomal rearrangement and resulting nucleophosmin (NPM1) -ALK fusion was first observed in 1994 in anaplastic large cell lymphoma (ALCL), a T-cell lymphoma responsive to cyclophosphamide, abriblastine, vincristine and prednisone in approximately 80% of cases; refractory cases usually respond favorably to brentuximab-vedotin. These treatments are regarded as a bridge to allogeneic hematopoietic stem cell transplantation (allo-SCT). Nowadays, transplant procedures and monitoring of chemotherapy patients proceed very slowly because the SARS-CoV-2 pandemic has heavily clogged the hospitals in all countries. Results: A 40-year-old Caucasian woman was first seen at our clinical center in June 2020. She had ALCL ALK +, a history of failure to two previous therapeutic lines and was in complete remission after 12 courses of Brentuximab, still pending allo-SCT after two failed donor selection. Facing of a new therapeutic failure, we requested the Italian drug regulatory agency, and obtained the authorization, to administer 250 mg twice a day of Crizotinib, a drug incomprehensibly not registered for ALCL ALK +. Conclusions: The response to Crizotinib was optimal, since no adverse event occurred, and CT-PET persisted negative; this drug has proved to be a valid bridge to allo-SCT

show abstract

“…Pain can inhibit effective coughing and deep breathing; consequently, pulmonary ventilation is reduced, with an increased risk of lung infections, especially in the elderly [ 25 , 26 ]. Furthermore, inadequate management of post-operative pain may contribute to the development of a post-thoracotomy chronic pain syndrome [ 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 ]. The complexity of the pathogenesis of pain due to trans-thoracic biopsy does not foresee univocal solutions, other than an early mobilization after surgery.…”

Section: Introductionmentioning

confidence: 99%

Chronic Chest Pain Control after Trans-Thoracic Biopsy in Mediastinal Lymphomas

et al. 2021

Self Cite

View full text Add to dashboard Cite

Chest pain following a trans-thoracic biopsy often has multiple etiologies, especially in patients with lymphomas. Pathological neuronal mechanisms integrate with an overproduction of IL-6, TNF-α, IL1-β by macrophages and monocytes, which amplifies inflammation and pain. In consideration of this complex pathogenesis, international guidelines recommend diversified analgesia protocols: thoracic epidural, paravertebral block, and systemic administration of opioids. This study reports an attempt to reduce chest pain and prevent chronic pain in 51 patients undergoing trans-thoracic biopsy for mediastinal lymphoma. The entity of pain, measured 72nd hour after biopsy by the Numerical Rating Scale (NRS), was compared with that seen at a 6th month checkpoint in 46 patients. The pain decreased in all cases. At the 6th month checkpoint, among 31 opioid-treated patients, none of the 16 patients with NRS < 6 within the 72nd hour post biopsy had developed chronic chest pain, while 8 of the 15 with higher values did (p < 0.01). Of 10 patients undergoing thoracotomy and treated with opioids, eight had a NRS of no more than 2, of which six had no chronic pain. Of the twenty-one patients who underwent VATS biopsy and were treated with opioids, fifteen had NRS no greater than 2, of which ten had no chronic pain. Subgroups of patients biopsied under mediastinotomy or video-assisted thoracoscopic surgery (VATS) and treated with thoracic epidural analgesia (TEA) or PVB were too small for such analysis.

show abstract

Clinical significance of serum triple monoclonal components: A report of 6 cases and a review of the literature

Cited by 9 publications

References 26 publications

Primary Cutaneous B-Cell Lymphomas: An Update

Primary Cutaneous B-Cell Lymphomas: An Update

How Fear of COVID-19 Can Affect Treatment Choices for Anaplastic Large Cell Lymphomas Alk+ Therapy: A Case Report

Chronic Chest Pain Control after Trans-Thoracic Biopsy in Mediastinal Lymphomas

Contact Info

Product

Resources

About